Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

1(25.0%)

Phase 2

1(25.0%)

Phase 4

1(25.0%)

Early Phase 1

1(25.0%)

4Total

N/A(1)

Phase 2(1)

Phase 4(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07228481Phase 4Completed

Study of Two Dosages of Roaccutane in Cystic Acne

Role: lead

NCT04971200Early Phase 1Completed

Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

Role: lead

NCT06032078Not ApplicableUnknown

Evaluation of the Responsiveness of Investigator Global Assessment Score for Keratosis Pilaris

Role: lead

NCT05525065Unknown

Investigating the Morbidity of Glucocorticoid Use in Patients With Autoimmune Bullous Diseases (AIBDs)

Role: lead

NCT05534776Unknown

Validation of 5-Point Investigator Global Assessments for Pemphigus

Role: lead

NCT05535517Unknown

Development and Validation of an Investigator Global Assessment Score for Keratosis Pilaris

Role: lead

NCT03016715Phase 2Unknown

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

Role: lead

All 7 trials loaded